Ardelyx Inc (ARDX)
8.035
-0.44
(-5.25%)
USD |
NASDAQ |
May 09, 15:57
Ardelyx Enterprise Value: 1.881B for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 08, 2024 | 1.881B |
| May 07, 2024 | 2.076B |
| May 06, 2024 | 2.038B |
| May 03, 2024 | 1.938B |
| May 02, 2024 | 1.486B |
| May 01, 2024 | 1.444B |
| April 30, 2024 | 1.395B |
| April 29, 2024 | 1.409B |
| April 26, 2024 | 1.399B |
| April 25, 2024 | 1.374B |
| April 24, 2024 | 1.402B |
| April 23, 2024 | 1.392B |
| April 22, 2024 | 1.420B |
| April 19, 2024 | 1.413B |
| April 18, 2024 | 1.404B |
| April 17, 2024 | 1.430B |
| April 16, 2024 | 1.467B |
| April 15, 2024 | 1.488B |
| April 12, 2024 | 1.549B |
| April 11, 2024 | 1.622B |
| April 10, 2024 | 1.565B |
| April 09, 2024 | 1.575B |
| April 08, 2024 | 1.610B |
| April 05, 2024 | 1.652B |
| April 04, 2024 | 1.572B |
| Date | Value |
|---|---|
| April 03, 2024 | 1.617B |
| April 02, 2024 | 1.615B |
| April 01, 2024 | 1.631B |
| March 31, 2024 | 1.605B |
| March 28, 2024 | 1.564B |
| March 27, 2024 | 1.590B |
| March 26, 2024 | 1.592B |
| March 25, 2024 | 1.657B |
| March 22, 2024 | 1.657B |
| March 21, 2024 | 1.687B |
| March 20, 2024 | 1.680B |
| March 19, 2024 | 1.732B |
| March 18, 2024 | 1.690B |
| March 15, 2024 | 1.750B |
| March 14, 2024 | 1.734B |
| March 13, 2024 | 1.876B |
| March 12, 2024 | 1.825B |
| March 11, 2024 | 1.841B |
| March 08, 2024 | 1.888B |
| March 07, 2024 | 1.953B |
| March 06, 2024 | 2.083B |
| March 05, 2024 | 2.097B |
| March 04, 2024 | 1.969B |
| March 01, 2024 | 2.039B |
| February 29, 2024 | 2.034B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
0.3966M
Minimum
Feb 23 2022
2.130B
Maximum
Feb 09 2024
473.45M
Average
410.24M
Median
Enterprise Value Benchmarks
| Nektar Therapeutics | -2.483M |
| Rigel Pharmaceuticals Inc | 176.70M |
| Omeros Corp | 245.84M |
| Vistagen Therapeutics Inc | -6.297M |
| Karyopharm Therapeutics Inc | 96.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.52M |
| Revenue (Quarterly) | 46.02M |
| Total Expenses (Quarterly) | 70.70M |
| EPS Diluted (Quarterly) | -0.11 |
| Gross Profit Margin (Quarterly) | 84.51% |
| Profit Margin (Quarterly) | -57.62% |
| Earnings Yield | -3.61% |
| Normalized Earnings Yield | -3.609 |